Description
Into its ninth year, this annual symposium strives to strengthen connections between academia and industry,
and between technology innovation and product development. The scientific session will feature an array of distinguished speakers presenting most recent advances in the life cycle
of drug discovery and development. The interactive panel discussions present strategies to reinvent biopharma R&D business model with the aim to enhance efficiency and success
rate from both regional and global perspectives. Through a format of knowledge sharing and networking, the goal is to promote innovation, collaboration, and support advancement
of San Diego’s biopharmaceutical research and development.
|
| 8:00 am - 5:00 pm |
Exhibition |
| 8:00 am - 8:45 am |
Continental Breakfast & Registration |
| 8:45 am - 9:00 am |
Welcome |
|
Hui Cai, Hui Cai, Ph.D., MBA, Chair of Board, SABPA, Vice President of Business Development, WuXi AppTec |
|
Opening Address |
|
The Honorable Brian P. Bilbray, Member of Congress |
| 9:00 am - 10:00 am |
Session I. Collaborative R&D-Industry and Academia
|
|
Session Chair : Peter Zhu M.S., M.B.A., EVP of SABPA SD, Sr. Scientist, Pfizers |
|
Pharmaceutical R&D in 2010 [slide] |
|
Diego Miralles, Head and Chief Medical Officer, J&J PRD West Coast |
|
Targeting Apoptotic Pathways for Cancer Therapy |
|
Xiaodong Wang, Director, National Institute of Biological Sciences, Beijing China |
| 10:00 am - 10:30 am |
Coffee Break |
| 10:30 am - 12:00 pm |
Session II (Plenary Discussion). Emerging Fields and Adapting Strategies
Description: The new decade has begun with a series of major scientific advances, continued turmoil in the pharmaceutical industry and financial markets, and a massive new healthcare reform law. This panel will offer perspectives for the future touching on several of these major developments. We will hear individual perspectives reflecting life science activities ranging from the cutting edge of diagnostics and therapeutics to the challenges of delivering “personalized medicine” to current trends in venture capital funding of innovative new companies and products.
|
|
Moderator : Lewis Shuster, CEO, Shuster Capitals |
|
John Dunn, Executive Vice President, New Ventures, Biogen-Idec |
|
Greg Heath, Sr. VP & General Manager, Diagnostics Business Unit, Illumina |
|
Steve Kaldor, President and CEO, Ambrx |
|
Bob More, General Partner, Frazier Healthcare Ventures |
|
Richard Neale, Chief Business Officer, Scripps Translational Science Institute |
| 12:00 pm - 1:30 pm |
Luncheon |
| 1:15 pm - 2:00 pm |
San Diego Bio-Pharma Achievement Award |
|
Session Chair : Xiangming Fang, President of SABPA SD, Sr. VP and CSO, eBioCenter Corporation |
|
Award Speech : Offshore Outsourcing of Pharmaceutical R&D |
|
Award Recipient : Ge Li, CEO, WuXi AppTec |
| 2:00 pm - 3:00 pm |
Session III. Drug Discovery in a Global Setting |
|
Session Chair : Mao Mao, Ph.D., Research Fellow, Pfizer |
|
The Pfizer Asia R&D Story |
|
Steve Yang, Vice President, Head of R&D, Asia at Pfizer |
|
Combining the Best of East and West: Drug Discovery Against the PI3K/mTOR Pathway |
|
Troy Wilson, President and CEO, Intellikine |
| 3:00 pm - 3:30 pm |
Coffee Break (/B) |
| 3:30 pm - 4:45 pm |
Session IV (Plenary Discussion). Stage 2 of China Life Sciences Industry (with Active Audience Participation)
Description: The last 10 years have seen the building of the first wave of life sciences in China. Successful CROs such as Wuxi have been built. Pharma has developed research centers. The first biotechs have put potential drugs into the clinic. Governments have helped support this industry and the returning of talent. China has widely been recognized as a necessary piece of any strategy. It has also been recognized for its competence. Likely this ten year period has succeeded most people’s wildest expectations (with the exception of a few visionaries like Ge Li, Xiaodong Wang, and Steve Yang who believed this years ago).
The next 10 years should bring an even more exciting and vibrant wave of change and excitement. The purpose of this panel is to discuss thoughts of the panel members and audience on this new wave. If you would like to propose any questions for the panel, please submit them to info@sdbiopharma.org. You may direct them to an individual and can list your name and organization, or leave them anonymous.
|
|
Moderator : John Oyler |
|
Nancy Chang, Chairman and Sr. Managing Director, Asia, OrbiMed |
|
James Tong, CFO, Chief Business & Development Officer, Tianyin Pharmaceutical, China |
|
Xiaodong Wang, Director, National Institute of Biological Sciences, Beijing China |
|
Steve Yang, Vice President, Head of R&D, Asia at Pfizer |
|
Guo-Liang Yu, President, CEO and Chairman of the Board, Epitomics |
| 4:45 pm |
Closing |
| |
| Final program as of June 1, 2010. All events will take place on June 5, 2010 (Saturday) at Hilton San Diego/Del Mar , Del Mar.
|
|
|
 |
